Bayer, Mammoth Biosciences to Collaborate on Gene Editing Technology

Montag, 10.01.2022 08:40 von PLX

• (PLX AI) – Bayer and Mammoth Biosciences to collaborate on novel gene editing technology.
• • Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more than one billion USD upon successful achievement
• • Option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies
• • Bayer will pay research funding and tiered royalties up to low double-digit percentage of net sales
• • The companies are also exploring work on ex vivo projects on a nonexclusive basis